Compositions containing Lactobacillus rhamnosus extract

Abstract

The present invention relates to a composition for topical application to keratinous materials, in particular the skin and / or lips, comprising, in a physiologically acceptable medium, at least one Lactobacillus rhamnosus extract (CNCM I-5313), one of its fractions and / or one of its metabolites, and at least one excipient selected from solvents other than water, UV filters, surfactants, gelling agents, thickeners, fillers, dyes, film-forming polymers, fragrances and mixtures thereof, and in particular to its use for promoting and / or improving barrier function.

Description

[Technical field]

[0001] The present invention relates to a composition comprising a novel extract of Lactobacillus rhamnosus, in particular a Lactobacillus rhamnosus lysate (CNCM I-5313), and its beneficial effect on keratinous materials, in particular the skin. [Background technology]

[0002] The skin is the main barrier of the human body. It protects the organs from damage caused by temperature, humidity differences and the external environment, such as ultraviolet radiation, stress, pollution and pathogenic microorganisms. However, excessive chemical and physical stimuli can deteriorate the normal functions of the skin and induce or accelerate its aging, leading to the appearance of wrinkles and loss of elasticity, flexibility and resilience.

[0003] The search for new molecules or active ingredients that can be used in cosmetics is necessary to develop products that give the skin a youthful, improved complexion and a radiant complexion without pigmentation or irregular coloring due to microcirculation.

[0004] The applicant has correctly demonstrated that a Lactobacillus rhamnosus extract, specifically a Lactobacillus rhamnosus lysate (CNCM I-5313), has a beneficial effect on in vitro skin cultures. The applicant has demonstrated that this lysate has an effect of promoting the expression of several genes, in particular those involved in: -Detoxification (MRP1=ABCC1, LONP1, GPX1), - Function of the mitochondrial respiratory chain involved in the generation of cellular energy (MT=NADH dehydrogenase / ubiquinone), - Hyaluronic acid secretion (MRP5), -Maintaining the integrity of cellular structures such as the cell nucleus (SYNE2, LMNA), and -The formation of some collagens and elastins (COL1A1, COL5A1, COL13A1, ELN).

[0005] Thus, the Lactobacillus rhamnosus extract according to the invention, and in particular Lactobacillus rhamnosus lysate (CNCM I-5313), is advantageous in that it exhibits a detoxifying and antioxidant effect, an anti-ageing effect targeting the reduction of wrinkles and loss of elasticity and density (collagen and elastin and the reference points between cells and these protein structures), a skin strengthening effect (cell structures such as the cell nucleus), an effect of adapting the skin to hypoxic stress, a depigmenting effect on skin spots (inhibition of melanin production) and / or an effect of normalizing the skin microflora by strengthening the innate immunity and the skin barrier. Summary of the Invention

[0006] A first subject of the present invention relates to a composition for topical application to keratinous materials, in particular the skin and / or the lips, comprising, in a physiologically acceptable medium, at least one Lactobacillus rhamnosus extract (CNCM I-5313), one of its fractions and / or one of its metabolites and at least one excipient chosen from solvents other than water, UV filters, surfactants, gelling agents, thickeners, fillers, dyes, film-forming polymers, fragrances and mixtures thereof, in particular at least one excipient chosen from solvents other than water, surfactants, gelling agents, thickeners, fillers, dyes, film-forming polymers, fragrances and mixtures thereof.

[0007] The present invention also relates to a non-therapeutic cosmetic method comprising applying at least one Lactobacillus rhamnosus extract according to the invention (CNCM I-5313) or a composition containing it to keratinous materials, the cosmetic method being intended to prevent and / or reduce the signs of skin ageing and / or to promote and / or improve the barrier function. The terms Lactobacillus rhamnosus (CNCM I-5313) or Lactobacillus rhamnosusCNCM I-5313 are used interchangeably and correspond to the Lactobacillus rhamnosus strain submitted, in accordance with the Budapest Treaty, on April 11, 2018 to the National Collection of Cultures of Microorganisms (CNCM) of the Institut Pasteur (28 rue du Docteur Roux, F-75024 Paris cedex 15) in the name of BIOVITIS, Le Bourg, 15400 SAINT-ETIENNE-DE-CHOMEIL, under the designation number [sic] CNCM I-5313.

[0008] The present invention also relates to the non-therapeutic cosmetic use of a Lactobacillus rhamnosus extract (CNCM I-5313) for promoting and / or improving the barrier function and / or reducing the signs of skin ageing.

[0009] Detailed Description of the Invention The present invention therefore relates in particular to a composition for topical application to keratinous materials, in particular the skin and / or the lips, comprising, in a physiologically acceptable medium, at least one Lactobacillus rhamnosus extract (CNCM I-5313), one of its fractions and / or one of its metabolites, and at least one excipient selected from solvents other than water, surfactants, gelling agents, thickeners, fillers, dyes, film-forming polymers, fragrances and mixtures thereof.

[0010] According to the invention, "keratinous materials" refers to the skin, mucous membranes (particularly the lips) and integuments. According to a particular embodiment, the composition is intended to be applied topically to the skin, lips or integuments, preferably to the skin.

[0011] "Keratinous material" according to the present invention is generally a healthy keratinous material, i.e. not exhibiting a condition or disorder resulting from a pathological condition (an "unhealthy" subject suffering from a pathology). The expressions healthy skin and / or lips or skin and / or lips are used interchangeably in the remainder of this specification.

[0012] By "physiologically acceptable medium" is meant a medium that is compatible with keratinous materials, and in particular with the skin and / or the lips.

[0013] According to the present invention, "excipient" means a substance that has no cosmetic effect in itself but is useful for incorporating the Lactobacillus rhamnosus extract into the composition of the present invention or its formulation.

[0014] Lactobacillus rhamnosus extract According to the definition of the international scientific association on probiotics and prebiotics, "probiotic" means live microorganisms that, when administered in adequate amounts, have a beneficial effect on the health of the host. "Prebiotic" means non-digestible food ingredients that induce specific changes in the composition and / or activity of the intestinal microflora, thereby conferring a beneficial effect on the host. "Synbiotic" means a product that contains both probiotics and prebiotics.

[0015] The Lactobacillus rhamnosus extract (probiotic microorganism) according to the invention may be included in the composition according to the invention in live, semi-active, inactivated or dead form. It may also be included in the form of fractions of cellular components or in the form of metabolites. The microorganism, metabolites or fractions may be introduced in the form of a lyophilized powder, in the form of a culture supernatant and / or, if applicable, in a concentrated form.

[0016] According to a particular embodiment, the Lactobacillus rhamnosus microorganism is carried out in an inactivated or killed form, more particularly in a lysate form.

[0017] Thus, according to a particularly preferred embodiment, the Lactobacillus rhamnosus extract according to the invention is a Lactobacillus rhamnosus lysate (CNCM I-5313) (non-viable), one of its fractions and / or one of its metabolites.

[0018] The terms "probiotic extract" or "Lactobacillus rhamnosus extract" or "probiotic lysate" or "Lactobacillus rhamnosus lysate" are used interchangeably.

[0019] By lysate is meant in particular a material obtained by lysis of cells of the microorganism of interest, releasing the intracellular biological components naturally contained in said cells. The lysate carried out consists of all or part of the intracellular biological components as well as the cell wall and membrane components. The invention therefore relates to a probiotic lysate and / or one of its fractions and / or one of its metabolites.

[0020] In the sense of the present invention, the term "fraction" more specifically denotes a fragment of said microorganism which, by analogy with all said microorganisms, at least in part exerts the same beneficial effect on the skin.

[0021] In particular, the lysate according to the present invention contains a cytoplasmic fraction of cells that contains enzymes (e.g., dehydrogenases, phosphatases, etc.) and / or cell wall components (e.g., peptidoglycan, etc.) and / or cell membrane components (e.g., glycerophospholipids, etc.).

[0022] Cells may be lysed using a variety of techniques well known to those skilled in the art, such as osmotic shock, heat shock, by ultrasound, and even under mechanical stress (eg centrifugation).

[0023] According to a preferred embodiment, the lysate is obtained by centrifugation and osmotic shock (eg, addition of sodium hydroxide).

[0024] According to a particular embodiment, the microorganisms are cultured anaerobically in a suitable medium. When the stationary phase of growth is reached, the medium can be inactivated, for example by pasteurization at a temperature of 60-65°C for 30 minutes. The microorganisms are then harvested by conventional separation techniques, for example by membrane filtration, centrifugation and resuspension in a physiologically sterile NaCl solution. A lysate is obtained by ultrasonic disruption of such a medium, so as to release the cytoplasmic fraction, cell wall fragments and products derived from metabolism. All naturally distributed components are then stabilized in a weakly acidic solution.

[0025] The solution thus obtained generally has a concentration of about 0.1% to 10% by weight, in particular 0.5% to 5% by weight, in particular 1% to 2% by weight, of active dry matter relative to the total weight of the wood.

[0026] Lysate can then be carried out in a variety of forms, such as a solution or a powder.

[0027] According to a particular embodiment, the lysate is in the form of a solution, preferably an aqueous solution, comprising from 0.1% to 10% by weight, in particular from 0.5% to 5% by weight, in particular from 1% to 2% by weight, of active dry matter relative to its total weight.

[0028] The probiotic microorganism according to the invention belongs to the species Lactobacillus rhamnosus (ATCC 7469, CCM 1825, NCDO 243, NCIB 6375 or WDCM 00101, depending on the collection submitted), preferably to the strain Lactobacillus rhamnosus CNCM I-5313, submitted under the designation CNCM I-5313, in accordance with the Budapest Treaty, on April 11, 2018, to the National Collection of Cultures of Microorganisms (CNCM) of the Institut Pasteur (28 rue du Docteur Roux, F-75024 Paris cedex 15), under the name of BIOVITIS, Le Bourg, 15400 SAINT-ETIENNE-DE-CHOMEIL, and / or one of its fractions and / or one of its metabolites.

[0029] The lysate of this L. rhamnosus strain is obtained according to the following protocol from the supplier Greentech: 1. Cultivate L. rhamnosus strains in a suitable medium; 2. Harvest the biomass by centrifugation; 3. Lyse the cells (by adding sodium hydroxide); 4. Adjust the pH (addition of citric acid) and dry matter (addition of sterile water) to obtain an active substance content in the range of 0.1% to 10% by weight, based on the total weight of the above solution, as dry matter (active substance); 5. Add a preservative (phenoxyethanol).

[0030] Such an L. rhamnosus lysate is referred to as Probiophyte LB by the supplier Greentech and its INCI name is defined as WATER AND LACTOBACILLUS FERMENT LYSATE AND PHENOXYETHANOL AND SODIUM HYDROXIDE AND CITRIC ACID, although the phenoxyethanol can be replaced by another preservative.

[0031] This lysate contains Lactobacillus rhamnosus as a dry matter (active substance) in a content ranging from 0.1% by weight to 10% by weight, specifically 0.5% by weight to 5% by weight, and particularly 1% by weight to 2% by weight, relative to the total weight of the lysate.

[0032] The L. rhamnosus lysate of the present invention may be formulated in the composition in an amount of at least 0.0001% by weight (expressed as dry weight or weight of active substance), in particular in an amount of 0.0001% to 10% by weight, more particularly in an amount of 0.0001% to 5% by weight, in particular in an amount of 0.0001% to 2% by weight, in particular in an amount of 0.0001% to 1% by weight, or even more particularly in an amount of 0.0001% to 0.05% by weight, based on the total weight of the composition.

[0033] According to one particular embodiment, Lactobacillus rhamnosus extract (CNCM I-5313) is present, as active substance, in a content ranging from 0.0001% to 0.05% by weight relative to the total weight of said composition.

[0034] The L. rhamnosus lysate according to the present invention may be used alone or in association with other probiotic microorganisms, prebiotic components, synbiotic components, or mixtures thereof.

[0035] According to a particular embodiment, the composition also comprises at least one cosmetic active substance other than vitamins or extracts containing them, in particular oils rich in essential fatty acids or otherwise, prebiotic extracts (promoting the growth of certain beneficial bacterial species of the skin microbiome and harming undesirable species), other extracts of other strains of probiotic microorganisms, or more particularly synbiotic components (probiotic extract + prebiotic extract), sebum regulators (promoting flora biodiversity) and stabilizers (limiting enlarged pores), emollients, protective active ingredients, in particular stimulators of the antioxidant and detoxification defenses in the skin (also known as antioxidants or simply antioxidants), depigmenting agents, exfoliating agents, anti-aging active ingredients, moisturizing ingredients, immunomodulatory active ingredients, and mixtures thereof.

[0036] By "composition" according to the present invention is meant a cosmetic or dermatological composition. According to one particular embodiment, it is a cosmetic composition. According to another particular embodiment, it is a dermatological composition. The compositions according to the invention can be used, for example, as care and / or make-up products for the face and / or body.

[0037] The compositions according to the invention are more particularly intended for topical application to keratinous materials, and in particular to the skin.

[0038] The composition of the invention comprises a physiologically acceptable medium, i.e. a medium compatible with the skin and integuments. The composition can have any cosmetic form, in particular an oil-in-water or water-in-oil emulsion or multiple emulsion, a microemulsion, a solution, a suspension, a lotion, a gel, a cream, a milk, a serum, a mist (aerosolized fluid solution), a stick or more particularly a powder and suitable for application to the skin, lips and / or integuments.

[0039] According to a particular embodiment, the composition according to the invention is intended to be applied topically to the skin and / or the lips and is in the form of a cosmetic care composition and / or a makeup composition for the skin and / or the lips.

[0040] The cosmetic composition of the present invention is advantageously in the form of an emulsion, serum or mist.

[0041] The compositions generally comprise at least one aqueous phase and at least one oil phase. The aqueous phase generally represents from 1% to 99% by weight relative to the total weight of the composition.

[0042] The oil phase according to the invention can comprise hydrocarbon oils, silicone oils, fluorinated or non-fluorinated oils, and mixtures thereof. These oils may be volatile or non-volatile, vegetable, mineral or synthetic.

[0043] Advantageously, hydrocarbon oils are used, especially those of vegetable origin.

[0044] Volatile hydrocarbon oils include C8-C16 branched alkanes, C8-C16 branched esters, and mixtures thereof.

[0045] Non-volatile hydrocarbon oils specifically include hydrocarbon oils, vegetable hydrocarbon oils, C10-C40 synthetic ethers, C10-C40 synthetic esters, C12-C26 fatty alcohols, C12-C22 higher fatty acids, and mixtures thereof.

[0046] The oil is present in the composition of the invention in a content ranging from 1% to 95% by weight relative to the total weight of the composition.

[0047] The compositions of the present invention may also contain any additives commonly used in cosmetics, such as UV filters, antioxidants, surfactants, gelling agents, fillers, dyes (e.g., pigments), preservatives, film-forming polymers, fragrances, cosmetic active ingredients such as emollients, moisturizers, vitamins, anti-aging agents, whitening agents, and mixtures thereof.

[0048] Cosmetic methods and other uses The present invention also relates to a non-therapeutic cosmetic method intended to prevent and / or reduce the signs of skin ageing and / or to promote and / or improve the barrier function, comprising applying to keratin materials at least one Lactobacillus rhamnosus extract (CNCM I-5313), in particular a Lactobacillus rhamnosus lysate (CNCM I-5313), one of its fractions and / or one of its metabolites, or a composition according to the invention as defined above.

[0049] Preferably, the keratinous material according to the present invention is a healthy keratinous material.

[0050] The Lactobacillus rhamnosus extract is generally present in a content ranging from 0.0001% to 10% by weight, in particular from 0.0001% to 5% by weight, preferably from 0.0001% to 2% by weight, in particular from 0.0001% to 1% by weight, or more particularly from 0.0001% to 0.05% by weight of dry matter relative to the total weight of the composition.

[0051] The composition implemented in this cosmetic method may be a care and / or makeup composition, in particular a care composition for the face and / or body skin.

[0052] Specifically, the method includes preventing and / or reducing loss of skin elasticity and density; The purpose is to prevent and / or reduce the appearance of wrinkles and / or fine lines and / or skin blemishes, improve the radiance and / or evenness of the skin, promote and / or improve skin hydration, detoxify the skin, promote and / or stimulate its antioxidant defences and / or improve the skin's resistance to hypoxia and / or control the skin microflora and / or stimulate skin immunity and the formation of the skin barrier.

[0053] "Promoting and / or stimulating the antioxidant defense of keratinous materials" means in particular promoting cutaneous oxygenation, thereby reducing the effects of cutaneous hypoxia and promoting cellular respiration and energy production at the cellular level.

[0054] "Promoting and / or stimulating skin immunity" means maintaining the balance of the skin microbiota and promoting skin homeostasis for healthier skin that is better protected from external agents.

[0055] According to certain embodiments, the methods of the invention are aimed at preventing and / or reducing loss of skin elasticity and density, preventing and / or reducing the appearance of wrinkles and / or fine lines and / or skin blemishes, improving skin radiance and / or evenness, promoting and / or improving skin hydration and / or improving skin resistance to hypoxia and / or controlling the skin microflora.

[0056] According to a particular embodiment, the composition of the invention is applied to aged skin, dull skin, tired skin or skin affected by an unfavourable or unbalanced diet, emotional stress or lack of sleep.

[0057] The present invention also relates to the non-therapeutic use of a Lactobacillus rhamnosus extract (CNCM I-5313) as a cosmetic for promoting and / or improving the barrier function of the skin and / or reducing the signs of skin ageing, in particular preventing and / or reducing loss of skin elasticity and density, preventing and / or reducing the appearance of wrinkles and / or fine lines and / or skin blemishes, improving skin radiance and / or evenness, promoting and / or improving skin moisture, detoxifying the skin, stimulating its antioxidant defences and / or improving the skin's resistance to hypoxia and / or controlling the skin microflora and / or stimulating skin immunity and the formation of the skin barrier.

[0058] According to a particular embodiment, the extract according to the invention is used for promoting and / or improving the barrier function and / or reducing the signs of skin ageing, in particular for preventing and / or reducing the loss of skin elasticity and density and / or preventing and / or reducing the appearance of wrinkles and / or fine lines and / or skin blemishes, improving skin radiance and / or evenness, promoting and / or improving skin hydration, detoxifying the skin and / or improving the skin's resistance to hypoxia and / or controlling the skin microflora.

[0059] The present invention also relates to the Lactobacillus rhamnosus extract CNCM I-5313 according to the invention for promoting and / or stimulating skin immunity.

[0060] The invention will now be illustrated by the following non-limiting examples. Unless otherwise indicated, percentages are expressed as weight percent based on the total weight of the composition. EXAMPLES

[0061] The applicant evaluated the effect of lysates of the probiotic bacterial strains L. rhamnosus: ATCC 7469, CCM 1825, NCDO 243, NCIB 6375 or WDCM 00101, depending on the collection submitted.

[0062] Specifically, probiotic bacterial strains were used that were submitted on April 11, 2018 to the National Collection of Cultures of Microorganisms (CNCM) of the Institut Pasteur (28 rue du Docteur Roux, F-75024 Paris cedex 15) under the name of BIOVITIS, Le Bourg, 15400 SAINT-ETIENNE-DE-CHOMEIL, designation CNCM I-5313, in accordance with the Budapest Treaty.

[0063] The lysate of this L. rhamnosus strain is obtained according to the following protocol from the supplier Greentech: 1. Cultivate L. rhamnosus strains in a suitable medium; 2. Harvest the biomass by centrifugation; 3. Lyse the cells (by adding sodium hydroxide); 4. Adjust the pH (addition of citric acid) and dry matter (addition of sterile water) to obtain an active substance content in the range of 0.01% to 10% by weight, as dry matter (active substance), based on the total weight of the above solution. 5. Optionally add a preservative (e.g., phenoxyethanol).

[0064] Such an L. rhamnosus lysate is named Probiophyte LB by the supplier Greentech and its INCI name is defined as WATER AND LACTOBACILLUS FERMENT LYSATE AND PHENOXYETHANOL AND SODIUM HYDROXIDE AND CITRIC ACID, although the phenoxyethanol can be replaced by another preservative.

[0065] This lysate contains Lactobacillus rhamnosus, as dry matter (active substance), in a content in the range of 0.1% to 10% by weight, specifically 0.5% to 5% by weight, in particular 1% to 2% by weight, and even more specifically 1.75% by weight, relative to the total weight of the lysate.

[0066] Such a solution (but without the phenoxyethanol preservative) was tested in skin cell culture tests at contents of 0.05%, 0.1% and 0.2% and was used in the cosmetic compositions for topical application exemplified below at contents ranging from 1% to 2% by weight of the raw material.

[0067] The terms Probiophyte LB or Lactobacillus rhamnosus lysate are used interchangeably in the following examples.

[0068] Example 1: Effect of L. rhamnosus extract on keratinocyte cultures In this test, we compared extracts from two different strains of probiotic bacteria and were able to select the extract that was most effective at stimulating skin cells. Using RT-qPCR, we were able to determine which extract was most effective at stimulating skin cells. It was possible to observe a stimulation or inhibition, or more particularly a lack of stimulation, of genes involved in the main skin care processes, specifically keratinocytes, the main cells of the epidermis.

[0069] Normal human keratinocytes (NHK) were cultured and then treated with the L. rhamnosus probiotic extracts described above or Lactococcus lactis extracts. After processing the NHKs, the extracted total RNA is reverse transcribed to obtain cDNA, which is then used to perform polymerase chain reaction (qPCR) testing for the genes being investigated.

[0070] Cells and culture conditions used: Cells: Passage 3 normal human keratinocytes (NHEK) Culture medium: Keratinocytes - 37°C, 5% CO2, SFM supplemented with 0.25ng / ml EGF, 25μg / ml pituitary extract and 25μg / ml gentamicin; Test medium: Keratinocyte-SFM supplemented with 25 μg / ml gentamicin

[0071] Compounds tested: - Probiophyte LB without preservatives: Lactobacillus rhamnosus extract according to the invention CNCM I-5313 - Lactococcus lactis extract: Lactococcus lactis extract provided by Greentech (product number 001119, batch number LYCC1204E1-BY, March 2012) containing Lactococcus lactis lysate, citric acid and sodium hydroxide. The dry matter (active) content of L. lactis is 5-6% of the weight of the raw material. Doses tested: 0.05%, 0.1% and 0.2% Processing time: 24h N=3 cultures for each experimental condition

[0072] Analyses performed: Measurement of gene expression by RT-qPCR on messenger RNA extracts from untreated cell layers (control) and cell layers treated with various concentrations of probiotic extract. Several genes were evaluated. The genes for which differential results were observed between the extract according to the invention (Probiophyte LB: Lactobacillus rhamnosus) and the comparative extract (Lactococcus lactis extract) and the corresponding results are shown in the table below.

[0073] RT-qPCR (RT-quantitative PCR) technology Obtaining total RNA Total RNA from each sample was isolated using TriPure Isolation Reagent® according to the supplier's recommended protocol. RNA quantity and quality were assessed by capillary electrophoresis (Bioanalyzer 2100, Agilent). Potential traces of DNA contamination were removed using the DNA-free system (Ambion).

[0074] Complementary DNA synthesis Complementary DNA (cDNA) was synthesized by reverse transcription of total RNA in the presence of oligo(dT) and the enzyme "Transcriptor First strand cDNA Synthesis" (Roche Diagnostics). cDNA was obtained and quantified with a spectrophotometer (Nanovue; GE Healthcare), after which the amount of cDNA was adjusted to 5ng / μl.

[0075] ·Quantitative PCR Polymerase chain reaction (PCR) was performed using a quantitative PCR (Light Cycler; Roche Molecular Systems Inc.) according to the supplier's recommended procedures.

[0076] The reaction mixture for each sample (10 μl final) contained: -2.5 μl of 5 ng / μl cDNA. -Primers for various markers used Reaction medium containing -taq DNA polymerase enzyme, SYBR Green I marker and MgCl2.

[0077] Data processing and statistical analysis Raw data was transferred to Microsoft Excel for processing. The incorporation of fluorescence into the amplified DNA was measured continuously during the PCR cycles. These measurements allowed obtaining a curve of fluorescence intensity as a function of the PCR cycles, thereby allowing the evaluation of the relative expression (RE) value of each marker.

[0078] The cycle number is determined from the "output" point of the fluorescence curve. The later the sample (more samples), the lower the initial mRNA copy number when the same marker is analyzed.

[0079] Relative expression (RE) values ​​are expressed in arbitrary units (AU) according to the following formula: "(1 / 2 サイクル数 ) x 10 6 "

[0080] [Table 1] [Table 2]

[0081] The results show the stimulatory effect of Probiophyte LB according to the invention on several keratinocyte genes in comparison with Lactococcus lactis extract.

[0082] The table above shows the stimulatory effect of Probiophyte LB on some important skin processes: - Formation of the skin barrier by stimulating the transglutaminase (TGM1) gene, which allows the formation of the keratinized envelope of keratinocytes, which ensures the mechanical and chemical resistance and hydrophobicity of the skin surface, as well as the organization of lipids on the skin surface; -Stimulating several genes for antimicrobial peptides that allow the control of the development of the skin microbiome: DEFB4A, S100A7, PI3, RNASE7, thus achieving innate immunity; -Strengthens the dermal-epidermal junction by stimulating the gene for collagen type 7 (COL7A1), which is a collagen that helps to seal the junction between the dermis and epidermis. This collagen decreases with age.

[0083] Example 2: Effect of L. rhamnosus extract on keratinocyte, melanocyte and fibroblast cell cultures In this second experiment, the TaqMan low density array (TLDA) method allows a larger repertoire of genes and a detailed study of the biological effects of Probiophyte LB on the three main cell types of the skin: keratinocytes, melanocytes and fibroblasts.

[0084] Cells used: Normal human keratinocytes (NHK) at passage 5, normal human fibroblasts at passage 6 and normal human melanocytes (NHM) at passage 7.

[0085] Compounds tested: -Probiophyte LB: Lactobacillus rhamnosus CNCM I-5313 extract without preservatives Doses tested: 0.1μg / ml and 0.2μg / ml Processing time: 24h N=3 cultures for each experimental condition

[0086] Analyses performed: Measurement of gene expression by RT-qPCR from messenger RNA extracts of untreated cell layers (control) and cell layers treated with different concentrations of Probiophyte LB.

[0087] TaqMan Low Density Array (TLDA) Technology Obtaining total RNA Remove the cell medium and add 250 μL of RLT lysis buffer (supplied with the Nucleospin RNA trace kit, Macherey-Nagel). Scrape the cells with a cell scraper and collect the cell lysate in a 1.2 mL deep well (supplied with the NucleoSpin RNA trace kit). Extract total RNA according to the defined protocol.

[0088] The resulting total RNA solution is assayed to confirm its quality using a microplate reader SPECTROstar Nano (BMG Labtech) combined with a Microlab STAR. The instrument is connected to a computer that controls the robotic platform and is equipped with dedicated software (MARS) to analyze the results. The technique requires a 384-well microplate (LoBase) and a positive control (RNA 250, AM7155, ThermoFisher) to validate the pipetting performed by the robot and the values ​​generated by the SPECTROstar Nano reader.

[0089] Complementary DNA synthesis The reverse transcription (RT) kit used is the Large Capacity Reverse Transcription Kit (ThermoFisher). It was used according to the protocol provided. 500 ng of total RNA is diluted in water to a final volume of 25 μL. It is then incubated for 10 min at 25°C and then 2 h at 37°C in the presence of 25 μL of the Large Capacity Reverse Transcription Kit 2X reaction mixture previously prepared as shown below. The different incubations are performed in a TRobot (Biometra).

[0090] [Table 3]

[0091] Large volume reverse transcription kit for one reaction 2X reaction medium ·PCR-TaqMan low density array 15 μL of each RT is mixed with 60 μL of water, followed by the addition of 75 μL of TaqMan Gene Expression Master Mix (ThermoFisher) containing DNA polymerase. After homogenization, 100 μL is applied to microfluidic cards containing probes corresponding to the genes tested, which are centrifuged and then sealed. The CD ROM corresponding to the profile of genes applied on the plate is loaded into the SDS 2.3 software, specifying the placement of each gene on the card. The control genes (or "endogenous genes") used to normalize the results are indicated before the start of PCR. This is done according to the protocol provided by Applied Biosystems for the ABI Prism 7900HT sequence detection system. The qPCR steps are 2 min at 50°C, 10 min at 94.5°C, followed by 30 s at 97°C and 59.7°C in 40 cycles.

[0092] statistical analysis Real-time quantitative PCR can be used if its validity is contained between 90% and 110%. For each sample, the cycle number at which the signal appears is determined by the SDS 2.3 software. In the same test, the expression level of the transcript of interest obtained is normalized to the value obtained with the housekeeping gene of beta-2-microglobulin. This gene, whose expression is constitutive and invariant, makes it possible to overcome any variations induced during the experiment (total RNA assay, pipetting, reverse transcription step, PCR in the instrument).

[0093] In the RT-PCR TLDA method, quantification is performed using the ΔΔCt comparative method. The obtained relative quantification (RQ) value corresponds here to the amplitude level of expression (x-fold higher or lower than the control) relative to the non-irradiated control. The RQ is calculated as follows, assuming the control is 1: "RQ = 2 -ΔΔCt = 2 -(ΔCt 処理 - ΔCt 未処理) " ΔCt treated = Ct treated target gene - Ct treated housekeeping gene ΔCt untreated = Ct untreated target gene - Ct untreated housekeeping gene

[0094] A Student's t-test is used to evaluate statistically significant variations in transcriptional activity. Each condition is performed in triplicate (3 untreated, 3 treated with the same conditions). A first Fisher's F-test is applied by comparing the two data matrices. If the values ​​are greater than α=0.05, the variance of the Student's t-test is 2, if the Fisher's F-test is less than α=0.05, the variance is 3. The transcriptional variation used is the one that corresponds to the Student's t-test less than α=0.05.

[0095] Results are shown as the mean of n = 3. Student's t-test is used to compare the effects of treated and untreated cells.

[0096] Results were considered significant at p<0.05 (*) or p<0.01 (**).

[0097] The results table below shows the effects of Probiophyte LB on several keratinocyte (NHK) genes, several melanocyte (NHM) and fibroblast (NHF) genes, complementary to those of previous studies.

[0098] A value smaller than 1 corresponds to an inhibitory effect on the expression of said gene, whereas a value larger than 1 corresponds to a stimulatory effect on the expression of said gene.

[0099] [Table 4]

[0100] [Table 5]

[0101] [Table 6-1] [Table 6-2]

[0102] These results indicate that dermal fibroblasts are more sensitive to their gene modification by Probiophyte LB (n=22 genes modified) than keratinocytes (n=2 genes regulated) and melanocytes (n=1 gene modified). Thus, this extract has a very large activity in dermal cells.

[0103] For dermal fibroblasts, in particular, we observe, by the Lactobacillus rhamnosus lysate according to the invention, the activation of genes involved in: - Cell-matrix adhesion and cohesion (ITGB1), which allows fibroblasts to compact and contract the matrix, a process that has a positive effect on elasticity; -Maintaining the integrity of cellular structures such as the nucleus and therefore the resistance of skin cells (SYNE2, LMNA); - the formation of several collagens and elastin, which are the main components of the dermis and whose stimulation counteracts the effects of aging (COL1A1, COL5A1, COL13A1, ELN); - Water balance in the dermis for water transport (AQP1) or water storage, the formation (HAS2 and 3), fixation (CD44) and secretion (ABCC5) of hyaluronan, which can hold up to 1000 times its weight in water; -Regeneration of dermal cells (Ki67) - Cellular antioxidant defense (GPX1) and detoxifier (ABCC1 = MRP1). These genes code for proteins that allow the excretion of toxic compounds from the cell; - cellular adaptation to hypoxic conditions (HIF1a), which increases with skin age and can be explained by the decrease in the dermal vascular network with age (see hypoxic markers such as carbonic anhydrase 9 in aged skin); -Energy and nutrients involving glucose entry into cells (SLC2A1); -Energy production in mitochondria (MT=NADH dehydrogenase or ubiquinone); - Detoxification and protection of mitochondria by degrading and recycling damaged mitochondrial proteins (LONP1).

[0104] The following are observed about keratinocytes: -Activation of a gene (TLR1) that is involved in innate immunity and is an immune surveillance receptor for bacterial components such as lipopeptides -Suppression of the gene (MMP9) involved in collagen degradation, which increases with age.

[0105] The following are observed in melanocytes: - Reduction in melanogenesis stimulating factor (PPARG) in these cells, which contributes to the depigmenting effect.

[0106] All the results show that the application of the Lactobacillus rhamnosus extract according to the invention (CNCM I-5313) to keratinous materials, and in particular to the skin, makes it possible to prevent and / or reduce the loss of elasticity and density of the skin, to prevent and / or reduce the appearance of wrinkles and / or fine lines and / or skin blemishes, to improve the radiance and / or smoothness of the skin, to promote and / or improve skin moisture, to detoxify the skin, to stimulate its antioxidant defences and / or to improve the skin's resistance to hypoxia and / or to regulate the skin microflora and / or to stimulate skin immunity and the formation of the skin barrier.

[0107] Example 3: Formulation The following formulations are prepared according to conventional formulation methods in the cosmetic field. [Table 7]

[0108] [Table 8]

[0109] Application of the composition to the skin reduces sebum levels, reduces pore size and improves skin texture. [Table 9]

[0110] Application of the composition to the skin imparts a healthy glow and radiance to the skin as well as skin color. [Table 10]

[0111] Applying the composition to the skin improves the evenness of skin tone. [Table 11]

[0112] Application of the composition to the skin imparts a healthy glow and radiance to the skin as well as skin color. [Table 12]

[0113] Application of the composition to the skin improves skin elasticity and imparts a healthy glow. [Table 13]

[0114] Application of the composition to the skin promotes and / or improves skin nourishment, imparting a healthy glow and radiance as well as skin colour. Furthermore, the present invention includes the following aspects. 1. A composition for topical application to keratinous materials, in particular the skin and / or the lips, comprising, in a physiologically acceptable medium, at least one Lactobacillus rhamnosus extract (CNCM I-5313), one of its fractions and / or one of its metabolites, and at least one excipient selected from solvents other than water, surfactants, gelling agents, thickening agents, fillers, dyes, film-forming polymers, fragrances and mixtures thereof, characterized in that it is a Lactobacillus rhamnosus lysate CNCM I-5313, one of its fractions and / or one of its metabolites. 2. The composition according to item 1, characterized in that the Lactobacillus rhamnosus lysate CNCM I-5313 is present in an amount of 0.1% to 10% by weight, particularly 0.5% to 5% by weight, in particular 1% to 2% by weight, based on the total weight of the composition, as active dry matter. 3. Compound according to item 1 or 2, characterized in that the Lactobacillus rhamnosus extract CNCM I-5313 is present as active substance (dry matter) in a content ranging from 0.0001% to 10% by weight, in particular from 0.0001% to 5% by weight, in particular from 0.0001% to 2% by weight, in particular from 0.0001% to 1% by weight or more in particular from 0.0001% to 0.05% by weight relative to the total weight of the composition. 4. The composition according to any one of items 1 to 3, characterized in that it further comprises at least one cosmetic active substance other than vitamins or extracts containing them, in particular an active substance selected from oils rich in essential fatty acids or otherwise, prebiotic extracts, other extracts of other strains of probiotic microorganisms or more particularly synbiotic components, sebum regulators and stabilizers, emollients, antioxidants, depigmenting agents, exfoliating agents, anti-aging active ingredients, moisturizing ingredients, immunomodulatory active ingredients and mixtures thereof. 5. The composition according to any one of items 1 to 4, which is in the form of an oil-in-water or water-in-oil emulsion or complex emulsion, microemulsion, solution, suspension, lotion, gel, cream, milk, serum, mist, stick, or more particularly powder. 6. The composition according to any one of items 1 to 5, which is a care and / or makeup product for the skin and / or lips. 7. A non-therapeutic cosmetic method intended to prevent and / or reduce the signs of skin ageing and / or to promote and / or improve the barrier function, comprising applying to keratinous materials at least one Lactobacillus rhamnosus extract CNCM I-5313, in particular a Lactobacillus rhamnosus lysate CNCM I-5313, one of its fractions and / or one of its metabolites, or a composition according to any one of claims 1 to 6. 8. The method according to item 7, characterized in that it aims to prevent and / or reduce loss of skin elasticity and / or density, prevent and / or reduce the appearance of wrinkles and / or fine lines and / or skin blemishes, improve skin radiance and / or smoothness, promote and / or improve skin moisture, detoxify the skin and / or improve skin resistance to hypoxia and / or control the skin microflora. 9. The method according to item 7 or 8, characterized in that the composition is applied to aged skin, lackluster skin, tired skin or skin affected by an unfavourable or unbalanced diet, emotional stress or lack of sleep. 10. Non-therapeutic use of a Lactobacillus rhamnosus extract CNCM I-5313, in particular a Lactobacillus rhamnosus lysate CNCM I-5313, one of its fractions and / or one of its metabolites, for promoting and / or improving the barrier function and / or reducing the signs of skin ageing, in particular preventing and / or reducing loss of skin elasticity and density, preventing and / or reducing the appearance of wrinkles and / or fine lines and / or skin blemishes, improving skin radiance and / or evenness, promoting and / or improving skin moisture, detoxifying the skin and / or improving the skin's resistance to hypoxia and / or controlling the skin microflora.

Claims

1. A composition for topical application to keratinous materials, comprising, in a physiologically acceptable medium, at least one Lactobacillus rhamnosus lysate CNCM I-5313 and at least one excipient selected from solvents other than water, surfactants, gelling agents, thickening agents, fillers, dyes, film-forming polymers, fragrances and mixtures thereof, The keratinous material is the skin and / or the lips, A composition, characterized in that the Lactobacillus rhamnosus lysate CNCM I-5313 is present in a content ranging from 0.0001% to 0.05% by weight, expressed as active dry matter, relative to the total weight of the composition.

2. 2. The composition according to claim 1, characterized in that it contains, as active dry matter, from 0.1% to 10% by weight of Lactobacillus rhamnosus lysate CNCM I-5313 relative to its total weight.

3. 3. The composition according to claim 1, further comprising at least one cosmetic active selected from the group consisting of oils, prebiotic extracts, extracts of other strains of probiotic microorganisms, synbiotic components (probiotic extract+prebiotic extract), sebum regulating agents, emollients, protective active ingredients, depigmenting agents, exfoliating agents, anti-ageing active ingredients, moisturizing ingredients, immunomodulating active ingredients and mixtures thereof.

4. 4. The composition according to claim 1, wherein the composition is in the form of an oil-in-water or water-in-oil emulsion or multiple emulsion, a microemulsion, a solution, a suspension, a lotion, a gel, a cream, a milk, a serum, a mist, a stick or more particularly a powder.

5. Composition according to any one of claims 1 to 4, characterized in that it is a care and / or makeup product for the skin and / or lips.

6. A non-therapeutic cosmetic method intended to prevent and / or reduce the signs of skin ageing and / or to promote and / or improve the barrier function, said method comprising applying a composition according to any one of claims 1 to 5 to a keratinous material, characterised in that the keratinous material is the skin and / or the lips.

7. 7. A non-therapeutic cosmetic method according to claim 6, characterized in that it aims to prevent and / or reduce loss of skin elasticity and / or density, prevent and / or reduce the appearance of wrinkles and / or fine lines and / or skin blemishes, improve skin radiance and / or evenness, promote and / or improve skin hydration, detoxify the skin and / or improve the skin's resistance to hypoxia and / or control the skin microflora.

8. 8. A non-therapeutic cosmetic method according to any one of claims 6 to 7, characterized in that the composition is applied to aged skin, lackluster skin, tired skin or skin affected by an unfavourable or unbalanced diet, emotional stress or lack of sleep.

9. A composition for non-therapeutic use comprising a Lactobacillus rhamnosus lysate CNCM I-5313 and at least one excipient chosen from solvents other than water, surfactants, gelling agents, thickeners, fillers, dyes, film-forming polymers, fragrances and mixtures thereof, wherein the Lactobacillus rhamnosus lysate CNCM I-5313 is present in a content ranging from 0.0001% to 0.05% by weight, as active dry matter, relative to the total weight of the composition, said non-therapeutic use being for the promotion and / or improvement of the barrier function and / or the reduction of the signs of skin aging.

10. A composition for non-therapeutic use comprising a Lactobacillus rhamnosus lysate CNCM I-5313 and at least one excipient selected from solvents other than water, surfactants, gelling agents, thickening agents, fillers, dyes, film-forming polymers, fragrances and mixtures thereof, in which the Lactobacillus rhamnosus lysate CNCM I-5313 is present in a content ranging from 0.0001% to 0.05% by weight, as active dry matter, relative to the total weight of the composition, said non-therapeutic use being for preventing and / or reducing loss of skin elasticity and density, preventing and / or reducing the appearance of wrinkles and / or fine lines and / or skin blemishes, improving skin radiance and / or evenness, promoting and / or improving skin moisture, detoxifying the skin and / or improving the skin's resistance to hypoxia and / or controlling the skin microflora.

Images